Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.40 |
| ▸ | CMA1 | P23946 | 8/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870369 | 0.89 | CTSS (0.43) | CTSSCMA1FAAHCES1DAGLA | |
| SCHEMBL8294638 | 0.82 | CTSS (0.47) | CTSSCTSLCTSBCTSK | |
| SCHEMBL3877761 | 0.80 | CTSS (0.49) | CTSSCTSLCTSKCYP3A4CYP2C9 | |
| SCHEMBL3873494 | 0.78 | FAAH (0.37) | CTSSFAAHCES1DAGLAXDH | |
| SCHEMBL3873335 | 0.76 | CMA1 (0.38) | CTSSCMA1FAAHCES1DAGLA | |
| SCHEMBL3869390 | 0.75 | CTSK (0.36) | CTSSCTSLCTSBCTSKCYP3A4 | |
| SCHEMBL3870467 | 0.73 | MMP1 (0.43) | CTSSFAAHCES1CTSBCTSK | |
| SCHEMBL3872609 | 0.73 | LIPG (0.35) | CTSSKDM4ECTSLCTSBCTSK | |
| SCHEMBL6248431 | 0.72 | CTSS (0.49) | CTSSCTSLCTSBCTSKCYP3A4 | |
| SCHEMBL5800404 | 0.72 | CTSS (0.43) | CTSSFAAHCES1DAGLACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482448-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189657-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSB, CTSS, CTSK | CTSS 2/4885CMA1 19/4885FAAH 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.